SER NYSE Pharmaceutical Preparations Financials FY2017βFY2025
Serina Therapeutics, Inc. had $0.1M of revenue in fiscal 2025, up 132.1% on the year before. Over five years, revenue changed β18.5% a year on average.
Last close Β· Oct 27, 2026
$1.67
β$3.40 (β67.06%) past year
Hi! I read Serina Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+132.1%
Yes. Sales grew 132.1% last year.
Does it make a profit?
β14,755.4%
No. It lost money last year.
Does profit turn into cash?
β13,856.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA summarises the numbers
Serina Therapeutics, Inc. had $0.1M of revenue in fiscal 2025, up 132.1% on the year before.
Over five years, revenue changed β18.5% a year on average.
Its operating margin was β18,478.5%, up 11,964.4Β pts: of every 100 in sales, about β18,478 is left after running the business.
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Loss periods are shown in red.
KIRA summarises the numbers
Serina Therapeutics, Inc. lost $19.2M in fiscal 2025.
Net income
Net income
Diluted EPS
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
KIRA summarises the numbers
Free cash flow was β$18.0M in fiscal 2025, β13,856.9% of revenue.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
In the last 12 months, insiders bought $0.1M and sold $0.4M of shares on the open market.
Bought, 12 months
$0.1M
4 insiders
Sold, 12 months
$0.4M
1 insider
Of sales under plans
100%
$0.4M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Stephen K. BrannanDirector | Bought | 1,000 | $2.03 | $0.0M | Form 4 |
| Jun 12, 2026 | Karen J WilsonDirector | Bought | 5,000 | $1.77 | $0.0M | Form 4 |
| Jun 11, 2026 | Karen J WilsonDirector | Bought | 5,100 | $1.75 | $0.0M | Form 4 |
| May 22, 2026 | Jay VenkatesanDirector | Bought | 589 | $1.78 | $0.0M | Form 4 |
| May 22, 2026 | Karen J WilsonDirector | Bought | 10,000 | $1.93 | $0.0M | Form 4 |
| May 21, 2026 | Karen J WilsonDirector | Bought | 10,000 | $1.77 | $0.0M | Form 4 |
| May 19, 2026 | Richard Peter MarshallDirector | Bought | 12,183 | $1.65 | $0.0M | Form 4 |
| Mar 23, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 6,500 | $2.86 | $0.0M | Form 4 |
| Mar 19, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 39,000 | $2.50 | $0.1M | Form 4 |
| Feb 2, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 6,500 | $3.03 | $0.0M | Form 4 |
| Jan 28, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 6,500 | $3.57 | $0.0M | Form 4 |
| Jan 22, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 2,500 | $2.95 | $0.0M | Form 4 |
| Jan 21, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 2,000 | $3.00 | $0.0M | Form 4 |
| Jan 20, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 2,000 | $3.07 | $0.0M | Form 4 |
| Jan 14, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 1,084 | $2.50 | $0.0M | Form 4 |
| Jan 13, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 5,416 | $2.50 | $0.0M | Form 4 |
| Jan 8, 2026 | Randall MoreadithChief Scientific Officer | Sold plan | 13,000 | $2.69 | $0.0M | Form 4 |
| Dec 23, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 4,100 | $2.60 | $0.0M | Form 4 |
| Dec 22, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 5,673 | $2.67 | $0.0M | Form 4 |
| Dec 16, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 3,227 | $2.96 | $0.0M | Form 4 |
| Dec 12, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 1,700 | $3.26 | $0.0M | Form 4 |
| Dec 11, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 3,555 | $3.24 | $0.0M | Form 4 |
| Dec 10, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 645 | $3.35 | $0.0M | Form 4 |
| Dec 9, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 600 | $3.31 | $0.0M | Form 4 |
| Dec 3, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 5,000 | $3.52 | $0.0M | Form 4 |
| Dec 2, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 1,500 | $3.91 | $0.0M | Form 4 |
| Nov 25, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 5,965 | $3.90 | $0.0M | Form 4 |
| Nov 24, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 535 | $3.94 | $0.0M | Form 4 |
| Nov 18, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 6,500 | $3.75 | $0.0M | Form 4 |
| Nov 10, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 6,500 | $4.10 | $0.0M | Form 4 |
| Nov 5, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 3,398 | $4.24 | $0.0M | Form 4 |
| Nov 4, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 3,102 | $4.40 | $0.0M | Form 4 |
| Oct 28, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 5,551 | $4.96 | $0.0M | Form 4 |
| Oct 27, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 949 | $5.19 | $0.0M | Form 4 |
| Oct 20, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 6,500 | $4.97 | $0.0M | Form 4 |
| Oct 13, 2025 | Randall MoreadithChief Scientific Officer | Sold plan | 4,326 | $5.20 | $0.0M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Serina Therapeutics, Inc. can carry it.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.6M | $0.6M | $7.6M | $3.7M | $3.1M |
| Debt incl. finance leases | $13.2M | $18.1M | β | β | β |
| Interest coverage | β7.2x | β2.1x | β0.6x | β32.4x | β112.8x |
| Current ratio | 0.2x | 0.2x | 5.4x | 2.4x | 1.7x |
| Quick ratio | 0.2x | 0.2x | 5.4x | 2.4x | 1.7x |
| Total assets | $3.2M | $3.2M | $9.0M | $6.7M | $7.0M |
| Total liabilities | $15.0M | $20.6M | $4.9M | $6.2M | $7.0M |
| Shareholders' equity | β$11.8M | β$37.8M | β$32.3M | $0.6M | β$0.0M |
| Net debt (β = net cash) | $12.6M | $17.5M | β | β | β |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
KIRA summarises the numbers
Serina Therapeutics, Inc. passes 2 of 7 financial health tests (Piotroski F-score).
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 0 / 7 | 3 / 8 | 2 / 8 | 2 / 8 | 2 / 9 | 4 / 8 | 0 / 7 | 2 / 7 |
| Accruals ratio | β3.1% | 4.9% | β22.0% | β53.6% | β23.2% | β141.5% | 126.9% | 76.4% | β17.9% |
| Altman Z'' | β | β23.17 | β47.95 | β103.63 | β141.03 | β148.72 | β16.85 | β35.19 | β50.64 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $1.4M | $1.4M | $1.7M | $0.4M | $0.1M | $0.0M | $3.2M | $0.1M | $0.1M |
| Gross profit | $1.2M | $1.0M | $1.5M | $0.3M | $0.1M | $0.0M | $0.1M | β | β |
| Research and development | $5.8M | $5.8M | $5.9M | $3.7M | $1.5M | $1.0M | $2.4M | $7.5M | $13.2M |
| Operating income | β$6.7M | β$11.2M | β$12.6M | β$10.1M | β$7.9M | β$7.0M | β$3.1M | β$17.0M | β$24.0M |
| Interest expense | β | β | β | β | $1.1M | $3.3M | $4.9M | $0.5M | $0.2M |
| Pretax income | β | β$7.7M | β$12.2M | β$11.1M | $8.7M | $10.5M | $5.3M | β$11.2M | β$19.2M |
| Income tax | β | β | $0.1M | β$0.2M | β | β | $0.0M | $0.0M | $0.0M |
| Net income | β$6.6M | β$7.5M | β$12.2M | β$10.9M | β$8.7M | β$10.5M | $5.3M | β$11.1M | β$19.2M |
| Net income to common | β | β | β | $10.4M | $8.6M | β | $5.3M | β$11.1M | β$19.4M |
| Diluted EPS | β$0.21 | β$0.21 | β$0.33 | β$0.29 | β$0.23 | β$9.70 | $0.73 | β$1.51 | β$1.91 |
| Diluted shares | 0.03B | 0.03B | 0.04B | 0.04B | 0.04B | 0.00B | 0.01B | 0.01B | 0.01B |
| Cash flow | |||||||||
| Cash from operations | β$6.3M | β$8.0M | β$10.2M | β$7.8M | β$7.9M | β$5.9M | β$2.5M | β$17.1M | β$18.0M |
| Capital expenditure | $0.0M | $0.0M | $0.6M | $0.0M | β | β | $0.5M | $0.0M | $0.1M |
| Free cash flow | β$6.3M | β$8.0M | β$10.8M | β$7.8M | β | β | β$3.0M | β$17.2M | β$18.0M |
| Depreciation and amortization | $0.2M | $0.1M | $0.4M | $0.7M | β | β | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | $0.1M | $1.3M | $1.9M | $0.9M | $1.0M | $0.8M | $0.0M | $2.6M | $3.8M |
| Balance sheet | |||||||||
| Cash and short-term investments | $7.4M | $6.7M | $2.4M | $0.5M | $0.6M | $0.6M | $7.6M | $3.7M | $3.1M |
| Total debt | β | β | β | β | $13.2M | $18.1M | β | β | β |
| Finance lease liabilities | β | β | β | β | β | β | $0.0M | $0.0M | β |
| Current assets | $7.6M | $7.9M | $4.1M | $2.3M | $2.2M | $2.5M | $7.6M | $5.7M | $6.1M |
| Current liabilities | β | $2.4M | $3.3M | $5.4M | $9.0M | $10.1M | $1.4M | $2.4M | $3.6M |
| Property and equipment, net | $0.1M | $0.1M | $1.1M | β | β | β | $0.6M | $0.5M | $0.5M |
| Intangible assets | $1.9M | $2.7M | $2.2M | $1.6M | $0.9M | $0.7M | $0.0M | β | β |
| Total assets | $9.6M | $10.7M | $7.4M | $3.9M | $3.2M | $3.2M | $9.0M | $6.7M | $7.0M |
| Total liabilities | $1.3M | $2.4M | $4.8M | $9.3M | $15.0M | $20.6M | $4.9M | $6.2M | $7.0M |
| Preferred stock | β | β | β | β | β | β | $0.0M | $0.0M | $4.9M |
| Shareholders' equity | $7.3M | $7.4M | $2.2M | β$5.1M | β$11.8M | β$37.8M | β$32.3M | $0.6M | β$0.0M |
| Margins | |||||||||
| Gross margin | 88.0% | 73.9% | 85.9% | 92.8% | 86.8% | 61.8% | 3.2% | β | β |
| Operating margin | β474.6% | β805.5% | β726.8% | β2,797.8% | β5,509.0% | β20,514.7% | β99.2% | β30,442.9% | β18,478.5% |
| EBITDA margin | β462.8% | β801.4% | β704.1% | β2,604.2% | β | β | β96.4% | β30,264.3% | β18,401.5% |
| Net margin | β468.7% | β537.4% | β703.4% | β3,009.7% | β6,024.3% | β30,770.6% | 167.1% | β19,894.6% | β14,755.4% |
| FCF margin | β447.7% | β574.2% | β625.1% | β2,170.9% | β | β | β94.5% | β30,641.1% | β13,856.9% |
| Returns | |||||||||
| Return on capital | β | β | β | β | β797.3% | β | β | β | β |
| Return on capital employed | β | β136.6% | β303.0% | 705.3% | 136.5% | 102.0% | β41.4% | β391.2% | β709.0% |
| Return on equity | β90.4% | β101.9% | β251.5% | β | β | β | β | β | β6,351.7% |
| Return on assets | β68.3% | β73.9% | β134.2% | β191.2% | β245.1% | β327.2% | 86.3% | β142.0% | β280.5% |
| Return on tangible equity | β121.7% | β158.3% | β18,140.3% | β | β | β | β | β1,738.1% | β |
| Growth | |||||||||
| Revenue growth | β | β0.6% | 23.8% | β79.1% | β60.1% | β76.4% | 9,173.5% | β98.2% | 132.1% |
| Net income growth | β | β | β | β | β | β | β | β311.4% | β |
| EPS growth | β | β | β | β | β | β | β | β306.8% | β |
| Share count change | β | 13.9% | 6.8% | 1.1% | 0.6% | β100.0% | 668,172.7% | 0.1% | 38.5% |
| Financial health | |||||||||
| Interest coverage | β | β | β | β | β7.2x | β2.1x | β0.6x | β32.4x | β112.8x |
| Current ratio | β | 3.2x | 1.2x | 0.4x | 0.2x | 0.2x | 5.4x | 2.4x | 1.7x |
| Quick ratio | β | 3.2x | 1.2x | 0.4x | 0.2x | 0.2x | 5.4x | 2.4x | 1.7x |
| Capital allocation | |||||||||
| Capex / revenue | 0.1% | 1.5% | 37.1% | 5.5% | β | β | 16.0% | 39.3% | 45.4% |
| Stock comp / revenue | 8.1% | 92.0% | 110.4% | 251.8% | 693.8% | 2,235.3% | 0.8% | 4,633.9% | 2,917.7% |
| Quality scores | |||||||||
| Piotroski F-score | β | 0.0 | 3.0 | 2.0 | 2.0 | 2.0 | 4.0 | 0.0 | 2.0 |
| Altman Z'' | β | β23.2 | β48.0 | β103.6 | β141.0 | β148.7 | β16.8 | β35.2 | β50.6 |
| Accruals ratio | β3.1% | 4.9% | β22.0% | β53.6% | β23.2% | β141.5% | 126.9% | 76.4% | β17.9% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001708599). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
